Close Menu

NEW YORK (GenomeWeb) — LexaGene said today that it has closed an oversubscribed private placement, grossing C$2.8 million ($2.1 million).

Through the transaction, Beverly, Massachusetts-based LexaGene — which trades on the Toronto Stock Exchange — sold roughly 4.4 million units consisting of one common share and one warrant for C$.65 apiece. Each warrant can be used to purchase a common share of the company for C$.85 and is exercisable over the next 15 months, subject to certain conditions that trigger an accelerated expiry.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May
22
Sponsored by
Stilla

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.